Hims & Hers to Launch an AI Agent Focused on the Weight-Loss Journey Amid Strategic Shifts Related to GLP-1s

Why It Matters

Embedding AI across the patient journey lets Hims & Hers retain customers and adapt quickly to shifting demand for weight‑loss drugs, strengthening its competitive edge in the fast‑growing telehealth market.

Key Takeaways

• AI weight‑loss companion to launch soon, enhancing patient engagement
• Labs AI already explains biomarker results with personalized context
• Revenue grew 4% YoY to $608.1 million after 69% 2024 surge
• Hims & Hers now sells branded Wegovy and Ozempic after Novo settlement
• AI team of ~40 engineers builds modular, no‑code telehealth platform

Pulse Analysis

The telehealth sector is increasingly leveraging artificial intelligence to differentiate services, and Hims & Hers is positioning itself at the forefront. By introducing an AI weight‑loss companion, the company seeks to guide users through diet, medication adherence, and lifestyle changes, delivering timely nudges that improve outcomes. This follows the launch of Labs AI, which translates complex biomarker data into actionable insights, demonstrating a broader strategy to embed AI at every touchpoint while preserving clinician oversight.

Hims & Hers’ AI architecture emphasizes modularity and low‑code flexibility, allowing rapid deployment of new agents as market needs evolve. The platform’s guardrails ensure that AI‑generated recommendations are reviewed by independent providers before reaching patients, addressing regulatory concerns and maintaining trust. With a dedicated team of roughly 40 AI specialists, the firm is re‑engineering its tech stack—adding a no‑code commercial engine, configurable clinical workflows, and an upgraded mobile experience—to support scalable, personalized care across multiple specialties.

Financially, the AI push comes as the company’s revenue growth moderates to 4% YoY, reaching $608.1 million after a 69% jump the prior year. A recent settlement with Novo Nordisk enables Hims & Hers to sell branded Wegovy and Ozempic, bolstering its weight‑loss portfolio amid intense competition. By marrying AI‑driven engagement with a robust drug offering, Hims & Hers aims to lock in higher lifetime value per customer and safeguard against future shifts in drug availability, positioning itself for sustained growth in the evolving digital health landscape.